NASDAQ : CBIO
Crescent Biopharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 13.39 USD (Oct 30, 2026, 2:56 PM EDT) · Market cap 573.11M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 576.96M |
| Enterprise Value | 406.80M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 37.14M |
| Shares Outstanding | 42.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 3.86% |
| Owned by Institutions (%) | 58.96% |
| Float | 27.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.55 |
| Forward PS | 807.75 |
| PB Ratio | 2.83 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 34.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.66 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -103.67% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $172,217 |
| Profits Per Employee | -$2.39M |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | +7.84% |
| 50-Day Moving Average | 15.62 |
| 200-Day Moving Average | 15.89 |
| Relative Strength Index (RSI) | 46.09 |
| Average Volume (20 Days) | 308,235 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.42M |
| Short Previous Month | 4.78M |
| Short % of Shares Out | 10.32% |
| Short % of Float | 16.35% |
| Short Ratio (days to cover) | 8.47 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 11.88M |
| Gross Profit | 11.88M |
| Operating Income | -170.24M |
| Pretax Income | -163.12M |
| Net Income | -165.12M |
| EBITDA | -170.03M |
| EBIT | -170.24M |
| Loss Per Share | -$6.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 171.59M |
| Total Debt | 1.44M |
| Net Cash | 170.16M |
| Net Cash Per Share | $3.98 |
| Equity (Book Value) | 163.26M |
| Book Value Per Share | 4.77 |
| Working Capital | 160.47M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -72.68M |
| Capital Expenditures | -939,000 |
| Depreciation & Amortization | 212,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -73.62M |
| FCF Per Share | -$1.72 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -1,432.63% |
| Pretax Margin | -1,372.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -44.74% |
| FCF Yield | -12.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $31.50 |
| Price Target Difference | 133.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -8.90% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.44 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |